drugset / Trial / NCT04967417
Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain Metastases
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase II single center, open-label, single arm study in patients with advanced non-small cell lung cancer (stage IV) with brain metastases. This study will be treated with combination of Pembrolizumab 200mg plus platinum doublet based on histology subtypes.
Timeline
- Start
- 2022-05-26
- Primary completion
- 2024-06-30
- Completion
- 2024-12-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | — |
| Subject | Carboplatin | Small molecule | 6 unknown | — |
| Subject | Paclitaxel | Small molecule | 200 mg/m2 | — |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | — |